Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Contemporary issues and the potential uses of capecitabine in metastatic breast cancer

Barrett-Lee, Peter, Bidard, François-Clément and Pierga, Jean-Yves 2009. Contemporary issues and the potential uses of capecitabine in metastatic breast cancer. Cancer Treatment Reviews 35 (7) , pp. 582-589. 10.1016/j.ctrv.2009.06.003

Full text not available from this repository.


Since its first regulatory approval more than 10 years ago, oncologists have gained wide experience in using the oral fluoropyrimidine, capecitabine, as monotherapy or in combination with other agents and the body of evidence supporting these approaches continues to grow. Alongside this increasing experience has been the appearance of new challenges in patient management. We now recognise several different biological subtypes of breast cancer, such as HER2-positive disease. The standard of care in these tumours comprises anti-HER2 therapy, and phase III data show that capecitabine can be effectively combined with such agents. Another increasingly prominent and currently unresolved issue resulting from more effective treatment of metastatic disease is the management of patients with brain metastases. The introduction of new, well-tolerated, oral chemotherapies also provides the opportunity for longer duration of therapy. These new clinical scenarios are discussed in the current review.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Subjects: R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
R Medicine > RM Therapeutics. Pharmacology
Uncontrolled Keywords: metastatic breast cancer, capecitabine, HER2, brain, targeted therapy
Publisher: Elsevier
ISSN: 0305-7372
Last Modified: 10 Oct 2017 14:07

Citation Data

Cited 10 times in Google Scholar. View in Google Scholar

Cited 10 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item